Maker of regenerative tissue products, neurosurgery devices and surgical instruments used in wound care and brain surgery.
Maker of regenerative tissue products, neurosurgery devices and surgical instruments used in wound care and brain surgery.
Sold to hospitals through a direct sales force and bought on surgeon preference and hospital contracts, with procedure volumes in neurosurgery and wound care driving reorders. Much of the portfolio was built through acquisitions of smaller device companies over many years.
Moat: narrow (regulatory licence, brand, installed base). Regulatory-approved regenerative-tissue brands with established surgeon relationships across two specialties.
Headquarters: Princeton, New Jersey · Founded: 1989 · Employees: 4,427
Size Integra LifeSciences (IART) is a United States Health Care company (Medical Specialties) with a market value of $1.08B, the 2182nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.86 on 18 Nov 2026.
Performance Over six months the shares fell 9.9%, against -4.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 0.8% over the last twelve months (peer median +10.4%); the operating margin is 11.6% (peer median 11.8%).
Valuation It trades at 6.0× forward earnings against a peer median of 18.5× (cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.1 points below its cost of capital (7.6% WACC).
Short interest Short interest is 10.2% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.66B | $1.64B | $1.61B | $1.54B | $1.56B |
| Revenue growth | — | +2% | +4% | -1% | — |
| Gross profit | $909M | $862M | $899M | $894M | $928M |
| EBITDA | $347M | $334M | $323M | $344M | $391M |
| Net income | $13.0M | -$516M | -$6.94M | $67.7M | $181M |
| Free cash flow | $85.8M | -$31.1M | $25.0M | $73.1M | $222M |
| Capital expenditure | $68.8M | $95.6M | $114M | $66.9M | $47.1M |
| Total debt | $2.00B | $2.03B | $1.98B | $1.68B | $1.62B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Integra LifeSciences IART | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% |
| Smith & Nephew SN..L | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% |
| Organogenesis ORGO | n/a | -67% | n/a | n/a | n/a | n/a |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Stryker SYK | $121B | -1% | +8% | 25% | 19.9× | 10.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IART | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.0% | -6.0% | 6th highest of 21 |
| 6-month return | -9.9% | -4.5% | 9th lowest of 20 |
| Distance from 52-week high | -32.4% | -29.4% | 10th lowest of 21 |
| Revenue growth (TTM) | +0.8% | +10.4% | 5th lowest of 19 |
| Operating margin | 11.6% | 11.8% | 10th lowest of 20 |
| Forward P/E | 6.0× | 18.5× | cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 5.9% | 8.2% | 5th least demanding of 13 |
| Growth delivered (Del g) | +3.6% | +10.1% | 4th lowest of 13 |
| Hurdle (Req g minus delivered) | +2.3 pp | -2.6 pp | 5th most demanding of 13 |
| ROIC minus cost of capital | -2.1 pp | +1.5 pp | 8th lowest of 19 |
| EV / EBITDA | 8.0× | 10.3× | 2nd cheapest of 7 |
| Net debt / EBITDA | 4.9× | -0.3× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |